Novo Nordisk's AI Bet Meets a Dose of Pricing Reality
Published on 04/15/2026 at 17:13 | Redaktion boerse-global.de
Novo Nordisk shares are caught between a bold technological future and a challenging commercial present. While the Danish pharmaceutical giant sealed a major partnership with OpenAI on April 14 to embed artificial intelligence across its research and supply chains, the market's focus remains fixed on near-term revenue pressures. This tension was underscored on April 15, as a price increase for its Wegovy pill was immediately overshadowed by a Wall Street downgrade.
Analysts at BMO Capital cut their price target on Novo Nordisk from $45 to $36, maintaining a "Market Perform" rating. Their concern centers on prescription data for the first quarter. Although an estimated 721,000 Wegovy pill prescriptions were written, IQVIA data suggests roughly 450,000 were for the lowest 1.5mg dose. This starter dose, priced at $149 per month in direct-to-consumer channels, generates significantly lower revenue. BMO now forecasts quarterly pill revenue of 881 million Danish kroner (DKK), a potential 12% miss compared to the consensus estimate of 1,001 million DKK.
The timing of the downgrade was pointed, arriving the same day Novo Nordisk raised the price of the higher 4mg Wegovy pill dose from $149 to $199 per month. The initial lower pricing was a strategic move to drive broad market adoption through pharmacies and telehealth providers. However, the current prescription mix indicates this strategy may be subduing near-term revenue growth.
Financially, the company maintains a robust foundation despite a severe share price decline. Full-year 2025 revenue reached 309.1 billion DKK, with approximately 60% derived from the US market. Capital expenditures rose to 60 billion DKK, partly due to the $16.5 billion acquisition of Catalent in late 2024. Management is also aggressively supporting the stock through a buyback program. A tranche of 3.8 billion DKK runs until May 4, and by April 10, the company had already repurchased about 11 million B-shares at an average price of 257.56 DKK.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The OpenAI alliance represents a strategic countermove to mounting competitive pressures. US rival Eli Lilly not only gained FDA approval for its oral weight-loss drug Foundayo in early April but also secured a partnership with Amazon Pharmacy for same-day delivery. Novo Nordisk's response is twofold: defend its GLP-1 market share with the new pill and next-generation drugs, while digitally transforming its operations. The partnership aims to integrate OpenAI's frontier models with Novo's in-house Gefion supercomputer, with full integration targeted for the end of 2026.
Beyond the core weight-loss and diabetes battle, Novo Nordisk is diversifying its pipeline. The drug candidate Etavopivat, for treating thalassemia, is advancing through regulatory processes in several markets. This move into rare blood disorders could open a revenue stream independent of the fiercely contested obesity market.
The stock's performance reflects the prevailing skepticism. Shares closed at 33.48 euros on April 15, marking a year-to-date loss of over 41% and trading more than 23% below its 200-day moving average. A Relative Strength Index (RSI) reading of 19.5 indicates the stock is deeply oversold. The price remains roughly 52% below its 52-week high of 70.13 euros from June 2025.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The coming weeks will deliver critical data points. First-quarter results in May will reveal the true financial impact of the Wegovy pill's launch. Later, the mid-2026 start of Medicare Part D coverage for obesity drugs in the US promises to dramatically expand patient access. By the end of 2026 or early 2027, the FDA is expected to decide on the approval of the combination drug CagriSema. For now, investors are weighing the promise of AI-driven efficiency against the immediate reality of a difficult pricing mix.
Ad
Novo Nordisk Stock: New Analysis - 15 April
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
